Oncolytic Virus Cancer Therapy Market
Market Insights on Oncolytic Virus Cancer Therapy covering sales outlook, demand forecast & up-to-date key trends
Oncolytic Virus Cancer Therapy Market by Virus Type, Application, End Use & Region | Forecast 2023 to 2033
Oncolytic Virus Cancer Therapy Market Snapshot (2023 to 2033)
The global oncolytic virus cancer therapy market is expected to be valued at US$ 22.86 Million in 2023 and is projected to exhibit a CAGR of 27% from 2023 to 2033. Overall, the industry is projected to reach a market value of US$ 250 Million as of 2033.
Oncolytic viruses (OVs), which have recently been identified as an effective anticancer tactic, are a kind of virus that can imitate selectively in tumor cells and constrain their development. OVT is a cancer treatment that employs a virus that can reconstruct itself to kill cancerous cells. There are multiple virus species, but not all of them can be engineered to be oncolytic viruses (OV).
The percentage of cancer cases worldwide has increased exponentially as a result of poor lifestyle decisions and visibility to carcinogens in various forms. This has prompted pharmacological companies to increase their investments in advanced therapeutics. Oncolytic virus cancer therapy has been a market forerunner. Considering the aforementioned facts and figures, the market is projected to exhibit a good rate of growth.
Report Attribute |
Details |
Expected Market Value (2023) |
US$ 22.86 Million |
Anticipated Forecast Value (2033) |
US$ 250 Million |
Projected Growth Rate (2023 to 2033) |
27% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Oncolytic Virus Cancer Therapy Demand Analysis vs. Forecast 2023 to 2033
Oncolytic research has gained popularity in recent years. During the past decade, the number of articles on oncolytic virus therapy studies enhanced by 395%. The oncolytic virus cancer therapy market witnessed enormous growth potential, and over 35 companies conducted clinical trials in this area. As a result, the market experienced high demand in the historical period.
The market for oncolytic virus therapies is expected to evolve in the coming years as a result of enhanced patient outcomes, diagnosis of cold tumors, a rich burgeoning pipeline, and easy production and administrative structure, which will permit drug companies to broaden their market penetration. Companies and academics are cooperating to evaluate obstacles and identify opportunities for oncolytic virus therapies Research and Development. The therapies in development are centered on novel strategies for treating/improving disease symptoms.
Which are Some Prominent Drivers of the Oncolytic Virus Cancer Therapy Market?
Administration awareness programs for early cancer detection drive Industry Growth
Governments in various developing regions have taken initiatives to increase consciousness about different cancer causes. To decrease death and morbidity rates, government agencies in developed and developing nations are performing education programs to inspire people to seek early diagnosis of cancer, which is anticipated to broaden the stream of patients who will be eligible for numerous new therapies.
For example, in the United Kingdom, Public Health England, an executive agency of the Department of Health and Social Care, launched the Be Clear on Cancer campaign to promote early cancer detection by increasing public awareness. Increasing awareness is likely to spur demand for cutting-edge cancer treatment and innovative treatments, with melanoma and breast cancer being the two most common cancers.
Surging Cancer Incidences around the world are fostering a Positive Perspective
Burgeoning cancer occurrences around the world are generating a positive perspective for the market. Because of their potent anti-tumor characteristics and ability to precisely target tumors without injuring adjacent tissues, oncolytic virus therapies are frequently used to treat a variety of cancers, including glioblastoma, breast, lung, and prostate cancer.
In line with this, the therapy's ubiquitous use to cure a wide variety of melanomas, such as hematological malignancies, lymphoma, leukemia, and myeloma, is boosting overall growth. Besides that, increasing patient concerns about the negative side effects of various cancer treatment options, such as invasive surgery, radiotherapy, chemotherapy, and immunotherapeutic, are driving market growth.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Projected to be Faced by the Market?
Treatment Side Effects Could Constrain Future Growth
Because oncolytic viruses have the ability to infect tissue and activate immune defense activity systems, they may cause antibodies that attack healthy cells, increasing the probability of infection. Possible adverse effects of the treatment, such as fever, shivers, dizziness, exhaustion, flu-like symptoms, and pain, may impede future growth, as patients may cautiously weigh these factors before desiring virus treatment.
Furthermore, a disparity in the demand and availability of resources necessary for the therapies may inhibit the service's overall growth and share. As an outcome, critical industrial participants and shareholders must hold these factors into account before investing in the market.
Region-Wise Insights
What Makes Asia Pacific the Largest Market for Oncolytic Virus Cancer?
Pharmaceutical companies are driving the Asia Pacific Market
The Asia Pacific region will hold the largest ownership stake in the Oncolytic Virus Cancer Therapy Market owing to a significant increase in the number of firms manufacturing medications for cancer treatment. As nations like China and Japan introduce breakthroughs into the market, the oncolytic virus therapy market is witnessing a rise in revenue and earnings.
Shanghai Sunway Biotech of China will contribute to market developments with the highest market share. The total oncolytic virus cancer therapy market share in Japan was US$ 2 Million in 2022, and it is anticipated to increase during the study period.
Why is North America Considered a Lucrative Region for the Oncolytic Virus Cancer Therapy Market?
North America is anticipated to grow at a Rapid Pace
North America is predicted to be the most valuable region for the worldwide oncolytic virus cancer therapy market over the upcoming years, with a substantial rate over the forecast period, owing to the region's high incidence of cancer, particularly melanoma cancer.
Furthermore, the region's significant presence of major producers and higher incidence of distributor sponsorship contribute to the greater accessibility of the oncolytic virus cancer therapy market. In 2021, the total market value for oncolytic virus therapies in the United States was US$ 8.5 Million, and this figure is expected to grow during the study period.
Furthermore, the market in North America is expected to expand at the fastest rate during the forecast timeframe, with a CAGR of 29.5%. Adequate spending for cancer research in the region, preceded by the existence of robust medical infrastructure in nations like the United States, is among the significant factors expected to fuel the region's overall growth.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Category-Wise Insights
Which End-User Segment Will Generate the Highest Market Revenue?
Hospitals to remain Primary Centers for disbursing Oncolytic Virus Cancer Therapy
Due to an expansion in the number of hospitals curing disease in developing nations, the hospital segment held the highest revenue share in 2021. Furthermore, increased patient prominence on effective and prompt disease management, as well as government investment in medical infrastructure, are cruising the growth of this segment.
Which Application Segment Will Hold the Highest Market Share?
Treatment for Sold Tumour Breast Cancer to acquire Precedence
The oncolytic virus cancer therapy market is divided into two applications: solid tumors and melanoma. With the solid tumor category, treatment for breast cancer is likely to account for the lion’s share. Breast cancer is the second most frequently diagnosed cancer worldwide, and current treatments are inadequate to heal metastatic breast cancer, as it is frequently affiliated with significant side effects that devastate patients' life quality.
Oncolytic Virus Cancer Therapy has emerged as a crucial tool for treating various types of cancer, including breast cancer. Pelareorep, for example, is an unchanged and intravenously conveyed oncolytic virus that entices an immune reaction in breast cancer survivors.
Startups Advancing Oncolytic Virus Cancer Therapy
The rising number of start-ups in the Oncolytic Virus Cancer Therapy Market has enhanced product quality and global sales. Furthermore, in order to gain a competitive edge, new start-ups are operating on recent developments and releasing new products such as:
- AdCure Bio, a startup headquartered in the United States that offers cancer viro-immunotherapies, was established in 2016. AdCure Bio is a cancer viro-immunotherapy manufacturer in the pre-clinical stage that is evolving potent and secure immuno-stimulatory oncolytic viruses for solid tumor therapy.
- Bionoxx, a South Korean startup established in 2016, evolves immune-oncology cancer treatments. The technologies developed by the startup integrates oncolytic vaccinia viruses, which ensure safety and maximize adaptive immunity. It encompasses a worldwide tumor-targeting antigen (UTTA) that strives out and destroys solid tumors along with remaining or recurring tumors.
Market Competition
Key players in the Oncolytic Virus Cancer Therapy Market are Oncolytics Biotech Inc., Amgen Inc., Sorrento Therapeutics, Transgene SA, Daiichi Sankyo Company, Shanghai Sunway Biotech Co, Ltd, Takara Bio Inc., PsiOxus Therapeutics, SillaJen Inc. and ViroCure.
- In August 2022, Amgen, based in the United States, agreed to spend $3.7 billion for the biopharma firm ChemoCentryx. Amgen will allow access to Tavneos, the firm's crucial therapy that has obtained therapy confirmation in the EU and Japan, as a result of this strategic initiative. With this procurement, Amgen can expand its reach and develop itself in regions such as Europe and the Asia Pacific.
- Bristol Myers Squibb and PsiOxus Therapeutics expanded their collaboration in April 2021 to research PsiOxus Therapeutics' cancer-killing virus. The collaboration will integrate Bristol's checkpoint reagent Opdivo and novel resource NG-641 in various types of tumors, based on the contract. NG-641 is based on the oncolytic virus 'enadenotucirev' developed by PsiOxus.
- Enara Bio and Boehringer Ingelheim entered into a strategic partnership and licensing contract for the development of a novel aimed at cancer immunotherapy in January 2021. The new partnership merges Boehringer's strategy for cancer treatment, which integrates science with innovative platforms like oncolytic viruses and cancer, with Enara's competence in cancer antigen recognition.
Report Scope
Report Attribute |
Details |
Market Value in 2023 |
US$ 22.86 Million |
Market Value in 2033 |
US$ 250 Million |
Growth Rate |
CAGR of 27% from 2023 to 2033 |
Base Year for Estimation |
2022 |
Historical Data |
2018 to 2022 |
Forecast Period |
2023 to 2033 |
Quantitative Units |
Revenue in US$ Million and CAGR from 2023 to 2033 |
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
Segments Covered |
|
Regions Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
Customization |
Available Upon Request |
Key Segments Profiled in the Oncolytic Virus Cancer Therapy Market Industry Survey
By Virus Type:
- Genetically Engineered Oncolytic Viruses
- Herpes Simplex Virus
- Adenovirus
- Vaccinia Virus
- Oncolytic Wild-type Viruses
- Reovirus
- Newcastle Disease Virus
- Vesicular Stomatitis Virus
By Application:
- Solid Tumor
- Breast Cancer
- Prostate Cancer
- Lung Cancer
- Glioblastoma
- Melanoma
- Hematological Malignancies
- Lymphoma
- Leukemia
- Myeloma
By End Use:
- Hospitals
- Specialty Clinics
- Cancer Research Institutes
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
What is the anticipated growth of the oncolytic virus cancer therapy market until 2033?
FMI projects the global oncolytic virus cancer therapy market to expand at a 27% value CAGR by 2033.
What is the estimated market value of the oncolytic virus cancer therapy market expected in 2023?
The global oncolytic virus cancer therapy market is estimated at a market value of US$ 22.86 Million.
What is the estimated market value of the oncolytic virus cancer therapy market expected in 2033?
The global oncolytic virus cancer therapy market is expected to garner a market value of US$ 250 Million.
Which region is forecast to be the most lucrative for oncolytic virus cancer therapy market growth?
FMI has projected North America to be one of the key regions for the oncolytic virus cancer therapy market.
Which are some prominent oncolytic virus cancer therapy providers?
Oncolytics Biotech Inc., Amgen Inc., Sorrento Therapeutics, Transgene SA, Daiichi Sankyo Company, Shanghai Sunway Biotech Co, Ltd, Takara Bio Inc., PsiOxus Therapeutics, SillaJen Inc., ViroCure.
Table of Content
1. Executive Summary | Oncolytic Virus Cancer Therapy Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Virus Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Virus Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Virus Type, 2023 to 2033 5.3.1. Genetically Engineered Oncolytic Viruses 5.3.1.1. Herpes Simplex Virus 5.3.1.2. Adenovirus 5.3.1.3. Vaccinia Virus 5.3.2. Oncolytic Wild-type Viruses 5.3.2.1. Reovirus 5.3.2.2. Newcastle Disease Virus 5.3.2.3. Vesicular Stomatitis Virus 5.4. Y-o-Y Growth Trend Analysis By Virus Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Virus Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033 6.3.1. Solid Tumors 6.3.1.1. Breast Cancer 6.3.1.2. Prostate Cancer 6.3.1.3. Lung Cancer 6.3.1.4. Glioblastoma 6.3.2. Melanoma 6.3.2.1. Hematological Malignancies 6.3.2.2. Lymphoma 6.3.2.3. Leukemia 6.3.2.4. Myeloma 6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-use 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End-use, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-use, 2023 to 2033 7.3.1. Hospitals 7.3.2. Specialty Clinics 7.3.3. Cancer Research Institutes 7.4. Y-o-Y Growth Trend Analysis By End-use, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By End-use, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. Asia Pacific 8.3.5. Middle East and Africa(MEA) 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Virus Type 9.2.3. By Application 9.2.4. By End-use 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Virus Type 9.3.3. By Application 9.3.4. By End-use 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Virus Type 10.2.3. By Application 10.2.4. By End-use 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Virus Type 10.3.3. By Application 10.3.4. By End-use 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Virus Type 11.2.3. By Application 11.2.4. By End-use 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Virus Type 11.3.3. By Application 11.3.4. By End-use 11.4. Key Takeaways 12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.1.4. Singapore 12.2.1.5. Thailand 12.2.1.6. Indonesia 12.2.1.7. Australia 12.2.1.8. New Zealand 12.2.1.9. Rest of Asia Pacific 12.2.2. By Virus Type 12.2.3. By Application 12.2.4. By End-use 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Virus Type 12.3.3. By Application 12.3.4. By End-use 12.4. Key Takeaways 13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. GCC Countries 13.2.1.2. South Africa 13.2.1.3. Israel 13.2.1.4. Rest of Middle East and Africa(MEA) 13.2.2. By Virus Type 13.2.3. By Application 13.2.4. By End-use 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Virus Type 13.3.3. By Application 13.3.4. By End-use 13.4. Key Takeaways 14. Key Countries Market Analysis 14.1. USA 14.1.1. Pricing Analysis 14.1.2. Market Share Analysis, 2022 14.1.2.1. By Virus Type 14.1.2.2. By Application 14.1.2.3. By End-use 14.2. Canada 14.2.1. Pricing Analysis 14.2.2. Market Share Analysis, 2022 14.2.2.1. By Virus Type 14.2.2.2. By Application 14.2.2.3. By End-use 14.3. Brazil 14.3.1. Pricing Analysis 14.3.2. Market Share Analysis, 2022 14.3.2.1. By Virus Type 14.3.2.2. By Application 14.3.2.3. By End-use 14.4. Mexico 14.4.1. Pricing Analysis 14.4.2. Market Share Analysis, 2022 14.4.2.1. By Virus Type 14.4.2.2. By Application 14.4.2.3. By End-use 14.5. Germany 14.5.1. Pricing Analysis 14.5.2. Market Share Analysis, 2022 14.5.2.1. By Virus Type 14.5.2.2. By Application 14.5.2.3. By End-use 14.6. United Kingdom 14.6.1. Pricing Analysis 14.6.2. Market Share Analysis, 2022 14.6.2.1. By Virus Type 14.6.2.2. By Application 14.6.2.3. By End-use 14.7. France 14.7.1. Pricing Analysis 14.7.2. Market Share Analysis, 2022 14.7.2.1. By Virus Type 14.7.2.2. By Application 14.7.2.3. By End-use 14.8. Spain 14.8.1. Pricing Analysis 14.8.2. Market Share Analysis, 2022 14.8.2.1. By Virus Type 14.8.2.2. By Application 14.8.2.3. By End-use 14.9. Italy 14.9.1. Pricing Analysis 14.9.2. Market Share Analysis, 2022 14.9.2.1. By Virus Type 14.9.2.2. By Application 14.9.2.3. By End-use 14.10. China 14.10.1. Pricing Analysis 14.10.2. Market Share Analysis, 2022 14.10.2.1. By Virus Type 14.10.2.2. By Application 14.10.2.3. By End-use 14.11. Japan 14.11.1. Pricing Analysis 14.11.2. Market Share Analysis, 2022 14.11.2.1. By Virus Type 14.11.2.2. By Application 14.11.2.3. By End-use 14.12. South Korea 14.12.1. Pricing Analysis 14.12.2. Market Share Analysis, 2022 14.12.2.1. By Virus Type 14.12.2.2. By Application 14.12.2.3. By End-use 14.13. Singapore 14.13.1. Pricing Analysis 14.13.2. Market Share Analysis, 2022 14.13.2.1. By Virus Type 14.13.2.2. By Application 14.13.2.3. By End-use 14.14. Thailand 14.14.1. Pricing Analysis 14.14.2. Market Share Analysis, 2022 14.14.2.1. By Virus Type 14.14.2.2. By Application 14.14.2.3. By End-use 14.15. Indonesia 14.15.1. Pricing Analysis 14.15.2. Market Share Analysis, 2022 14.15.2.1. By Virus Type 14.15.2.2. By Application 14.15.2.3. By End-use 14.16. Australia 14.16.1. Pricing Analysis 14.16.2. Market Share Analysis, 2022 14.16.2.1. By Virus Type 14.16.2.2. By Application 14.16.2.3. By End-use 14.17. New Zealand 14.17.1. Pricing Analysis 14.17.2. Market Share Analysis, 2022 14.17.2.1. By Virus Type 14.17.2.2. By Application 14.17.2.3. By End-use 14.18. GCC Countries 14.18.1. Pricing Analysis 14.18.2. Market Share Analysis, 2022 14.18.2.1. By Virus Type 14.18.2.2. By Application 14.18.2.3. By End-use 14.19. South Africa 14.19.1. Pricing Analysis 14.19.2. Market Share Analysis, 2022 14.19.2.1. By Virus Type 14.19.2.2. By Application 14.19.2.3. By End-use 14.20. Israel 14.20.1. Pricing Analysis 14.20.2. Market Share Analysis, 2022 14.20.2.1. By Virus Type 14.20.2.2. By Application 14.20.2.3. By End-use 15. Market Structure Analysis 15.1. Competition Dashboard 15.2. Competition Benchmarking 15.3. Market Share Analysis of Top Players 15.3.1. By Regional 15.3.2. By Virus Type 15.3.3. By Application 15.3.4. By End-use 16. Competition Analysis 16.1. Competition Deep Dive 16.1.1. Oncolytics Biotech Inc. 16.1.1.1. Overview 16.1.1.2. Product Portfolio 16.1.1.3. Profitability by Market Segments 16.1.1.4. Sales Footprint 16.1.1.5. Strategy Overview 16.1.1.5.1. Marketing Strategy 16.1.2. Amgen Inc. 16.1.2.1. Overview 16.1.2.2. Product Portfolio 16.1.2.3. Profitability by Market Segments 16.1.2.4. Sales Footprint 16.1.2.5. Strategy Overview 16.1.2.5.1. Marketing Strategy 16.1.3. Sorrento Therapeutics 16.1.3.1. Overview 16.1.3.2. Product Portfolio 16.1.3.3. Profitability by Market Segments 16.1.3.4. Sales Footprint 16.1.3.5. Strategy Overview 16.1.3.5.1. Marketing Strategy 16.1.4. Transgene SA 16.1.4.1. Overview 16.1.4.2. Product Portfolio 16.1.4.3. Profitability by Market Segments 16.1.4.4. Sales Footprint 16.1.4.5. Strategy Overview 16.1.4.5.1. Marketing Strategy 16.1.5. Daiichi Sankyo Company 16.1.5.1. Overview 16.1.5.2. Product Portfolio 16.1.5.3. Profitability by Market Segments 16.1.5.4. Sales Footprint 16.1.5.5. Strategy Overview 16.1.5.5.1. Marketing Strategy 16.1.6. Shanghai Sunway Biotech Co, Ltd 16.1.6.1. Overview 16.1.6.2. Product Portfolio 16.1.6.3. Profitability by Market Segments 16.1.6.4. Sales Footprint 16.1.6.5. Strategy Overview 16.1.6.5.1. Marketing Strategy 16.1.7. Takara Bio Inc. 16.1.7.1. Overview 16.1.7.2. Product Portfolio 16.1.7.3. Profitability by Market Segments 16.1.7.4. Sales Footprint 16.1.7.5. Strategy Overview 16.1.7.5.1. Marketing Strategy 16.1.8. PsiOxus Therapeutics 16.1.8.1. Overview 16.1.8.2. Product Portfolio 16.1.8.3. Profitability by Market Segments 16.1.8.4. Sales Footprint 16.1.8.5. Strategy Overview 16.1.8.5.1. Marketing Strategy 16.1.9. SillaJen Inc 16.1.9.1. Overview 16.1.9.2. Product Portfolio 16.1.9.3. Profitability by Market Segments 16.1.9.4. Sales Footprint 16.1.9.5. Strategy Overview 16.1.9.5.1. Marketing Strategy 16.1.10. ViroCure 16.1.10.1. Overview 16.1.10.2. Product Portfolio 16.1.10.3. Profitability by Market Segments 16.1.10.4. Sales Footprint 16.1.10.5. Strategy Overview 16.1.10.5.1. Marketing Strategy 17. Assumptions & Acronyms Used 18. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Virus Type, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Application, 2018 to 2033 Table 4: Global Market Value (US$ Million) Forecast by End-use, 2018 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Virus Type, 2018 to 2033 Table 7: North America Market Value (US$ Million) Forecast by Application, 2018 to 2033 Table 8: North America Market Value (US$ Million) Forecast by End-use, 2018 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 10: Latin America Market Value (US$ Million) Forecast by Virus Type, 2018 to 2033 Table 11: Latin America Market Value (US$ Million) Forecast by Application, 2018 to 2033 Table 12: Latin America Market Value (US$ Million) Forecast by End-use, 2018 to 2033 Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: Europe Market Value (US$ Million) Forecast by Virus Type, 2018 to 2033 Table 15: Europe Market Value (US$ Million) Forecast by Application, 2018 to 2033 Table 16: Europe Market Value (US$ Million) Forecast by End-use, 2018 to 2033 Table 17: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 18: Asia Pacific Market Value (US$ Million) Forecast by Virus Type, 2018 to 2033 Table 19: Asia Pacific Market Value (US$ Million) Forecast by Application, 2018 to 2033 Table 20: Asia Pacific Market Value (US$ Million) Forecast by End-use, 2018 to 2033 Table 21: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 22: MEA Market Value (US$ Million) Forecast by Virus Type, 2018 to 2033 Table 23: MEA Market Value (US$ Million) Forecast by Application, 2018 to 2033 Table 24: MEA Market Value (US$ Million) Forecast by End-use, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Million) by Virus Type, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Application, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by End-use, 2023 to 2033 Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 8: Global Market Value (US$ Million) Analysis by Virus Type, 2018 to 2033 Figure 9: Global Market Value Share (%) and BPS Analysis by Virus Type, 2023 to 2033 Figure 10: Global Market Y-o-Y Growth (%) Projections by Virus Type, 2023 to 2033 Figure 11: Global Market Value (US$ Million) Analysis by Application, 2018 to 2033 Figure 12: Global Market Value Share (%) and BPS Analysis by Application, 2023 to 2033 Figure 13: Global Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033 Figure 14: Global Market Value (US$ Million) Analysis by End-use, 2018 to 2033 Figure 15: Global Market Value Share (%) and BPS Analysis by End-use, 2023 to 2033 Figure 16: Global Market Y-o-Y Growth (%) Projections by End-use, 2023 to 2033 Figure 17: Global Market Attractiveness by Virus Type, 2023 to 2033 Figure 18: Global Market Attractiveness by Application, 2023 to 2033 Figure 19: Global Market Attractiveness by End-use, 2023 to 2033 Figure 20: Global Market Attractiveness by Region, 2023 to 2033 Figure 21: North America Market Value (US$ Million) by Virus Type, 2023 to 2033 Figure 22: North America Market Value (US$ Million) by Application, 2023 to 2033 Figure 23: North America Market Value (US$ Million) by End-use, 2023 to 2033 Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 28: North America Market Value (US$ Million) Analysis by Virus Type, 2018 to 2033 Figure 29: North America Market Value Share (%) and BPS Analysis by Virus Type, 2023 to 2033 Figure 30: North America Market Y-o-Y Growth (%) Projections by Virus Type, 2023 to 2033 Figure 31: North America Market Value (US$ Million) Analysis by Application, 2018 to 2033 Figure 32: North America Market Value Share (%) and BPS Analysis by Application, 2023 to 2033 Figure 33: North America Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033 Figure 34: North America Market Value (US$ Million) Analysis by End-use, 2018 to 2033 Figure 35: North America Market Value Share (%) and BPS Analysis by End-use, 2023 to 2033 Figure 36: North America Market Y-o-Y Growth (%) Projections by End-use, 2023 to 2033 Figure 37: North America Market Attractiveness by Virus Type, 2023 to 2033 Figure 38: North America Market Attractiveness by Application, 2023 to 2033 Figure 39: North America Market Attractiveness by End-use, 2023 to 2033 Figure 40: North America Market Attractiveness by Country, 2023 to 2033 Figure 41: Latin America Market Value (US$ Million) by Virus Type, 2023 to 2033 Figure 42: Latin America Market Value (US$ Million) by Application, 2023 to 2033 Figure 43: Latin America Market Value (US$ Million) by End-use, 2023 to 2033 Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 48: Latin America Market Value (US$ Million) Analysis by Virus Type, 2018 to 2033 Figure 49: Latin America Market Value Share (%) and BPS Analysis by Virus Type, 2023 to 2033 Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Virus Type, 2023 to 2033 Figure 51: Latin America Market Value (US$ Million) Analysis by Application, 2018 to 2033 Figure 52: Latin America Market Value Share (%) and BPS Analysis by Application, 2023 to 2033 Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033 Figure 54: Latin America Market Value (US$ Million) Analysis by End-use, 2018 to 2033 Figure 55: Latin America Market Value Share (%) and BPS Analysis by End-use, 2023 to 2033 Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End-use, 2023 to 2033 Figure 57: Latin America Market Attractiveness by Virus Type, 2023 to 2033 Figure 58: Latin America Market Attractiveness by Application, 2023 to 2033 Figure 59: Latin America Market Attractiveness by End-use, 2023 to 2033 Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 61: Europe Market Value (US$ Million) by Virus Type, 2023 to 2033 Figure 62: Europe Market Value (US$ Million) by Application, 2023 to 2033 Figure 63: Europe Market Value (US$ Million) by End-use, 2023 to 2033 Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 68: Europe Market Value (US$ Million) Analysis by Virus Type, 2018 to 2033 Figure 69: Europe Market Value Share (%) and BPS Analysis by Virus Type, 2023 to 2033 Figure 70: Europe Market Y-o-Y Growth (%) Projections by Virus Type, 2023 to 2033 Figure 71: Europe Market Value (US$ Million) Analysis by Application, 2018 to 2033 Figure 72: Europe Market Value Share (%) and BPS Analysis by Application, 2023 to 2033 Figure 73: Europe Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033 Figure 74: Europe Market Value (US$ Million) Analysis by End-use, 2018 to 2033 Figure 75: Europe Market Value Share (%) and BPS Analysis by End-use, 2023 to 2033 Figure 76: Europe Market Y-o-Y Growth (%) Projections by End-use, 2023 to 2033 Figure 77: Europe Market Attractiveness by Virus Type, 2023 to 2033 Figure 78: Europe Market Attractiveness by Application, 2023 to 2033 Figure 79: Europe Market Attractiveness by End-use, 2023 to 2033 Figure 80: Europe Market Attractiveness by Country, 2023 to 2033 Figure 81: Asia Pacific Market Value (US$ Million) by Virus Type, 2023 to 2033 Figure 82: Asia Pacific Market Value (US$ Million) by Application, 2023 to 2033 Figure 83: Asia Pacific Market Value (US$ Million) by End-use, 2023 to 2033 Figure 84: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033 Figure 85: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 88: Asia Pacific Market Value (US$ Million) Analysis by Virus Type, 2018 to 2033 Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by Virus Type, 2023 to 2033 Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by Virus Type, 2023 to 2033 Figure 91: Asia Pacific Market Value (US$ Million) Analysis by Application, 2018 to 2033 Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Application, 2023 to 2033 Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033 Figure 94: Asia Pacific Market Value (US$ Million) Analysis by End-use, 2018 to 2033 Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by End-use, 2023 to 2033 Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by End-use, 2023 to 2033 Figure 97: Asia Pacific Market Attractiveness by Virus Type, 2023 to 2033 Figure 98: Asia Pacific Market Attractiveness by Application, 2023 to 2033 Figure 99: Asia Pacific Market Attractiveness by End-use, 2023 to 2033 Figure 100: Asia Pacific Market Attractiveness by Country, 2023 to 2033 Figure 101: MEA Market Value (US$ Million) by Virus Type, 2023 to 2033 Figure 102: MEA Market Value (US$ Million) by Application, 2023 to 2033 Figure 103: MEA Market Value (US$ Million) by End-use, 2023 to 2033 Figure 104: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 105: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 106: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 107: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 108: MEA Market Value (US$ Million) Analysis by Virus Type, 2018 to 2033 Figure 109: MEA Market Value Share (%) and BPS Analysis by Virus Type, 2023 to 2033 Figure 110: MEA Market Y-o-Y Growth (%) Projections by Virus Type, 2023 to 2033 Figure 111: MEA Market Value (US$ Million) Analysis by Application, 2018 to 2033 Figure 112: MEA Market Value Share (%) and BPS Analysis by Application, 2023 to 2033 Figure 113: MEA Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033 Figure 114: MEA Market Value (US$ Million) Analysis by End-use, 2018 to 2033 Figure 115: MEA Market Value Share (%) and BPS Analysis by End-use, 2023 to 2033 Figure 116: MEA Market Y-o-Y Growth (%) Projections by End-use, 2023 to 2033 Figure 117: MEA Market Attractiveness by Virus Type, 2023 to 2033 Figure 118: MEA Market Attractiveness by Application, 2023 to 2033 Figure 119: MEA Market Attractiveness by End-use, 2023 to 2033 Figure 120: MEA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports